PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.45%
R&D change of 20.45% versus flat Biotechnology spending. Walter Schloss would verify adequacy.
69.30%
G&A change of 69.30% versus flat Biotechnology overhead. Walter Schloss would verify efficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.79%
Operating expenses growth exceeding 1.5x Biotechnology median of 0.43%. Jim Chanos would check for waste.
30.79%
Total costs growth exceeding 1.5x Biotechnology median of 1.35%. Jim Chanos would check for waste.
No Data
No Data available this quarter, please select a different quarter.
1.90%
D&A growth exceeding 1.5x Biotechnology median of 0.89%. Jim Chanos would check for overinvestment.
-31.40%
EBITDA decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-30.79%
Operating income decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-10.20%
Other expenses reduction while Biotechnology median is -2.93%. Seth Klarman would investigate advantages.
-31.28%
Pre-tax income decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-264.58%
Tax expense reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-31.28%
Net income decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-21.00%
EPS decline while Biotechnology median is 6.12%. Seth Klarman would investigate causes.
-22.22%
Diluted EPS decline while Biotechnology median is 6.12%. Seth Klarman would investigate causes.
7.78%
Share count reduction below 50% of Biotechnology median of 0.49%. Jim Chanos would check for issues.
7.68%
Diluted share reduction below 50% of Biotechnology median of 0.51%. Jim Chanos would check for issues.